Diseases
Diseases
Measles
A very contagious virus causing fever and rash; can cause pneumonia and brain swelling.
| How common now (UK) | 2025 958 lab-confirmed cases in England in 2025 (2,911 in 2024). 3 measles-related deaths registered in England & Wales in 2025 (1 acute child death in a child with an immune problem; 2 adult late effects). source |
|---|---|
| How common now (US) | 2025 2,289 confirmed cases in 2025 (incl. 26 international visitors); 3 deaths. (CDC's NNDSS summary table gives 1,975 for 2025 - different counting.) source |
| How often it kills | 1 to 3 of every 1,000 children with measles die (US). source |
| Treatment if caught | No specific antiviral. Supportive care; CDC advises vitamin A for children with measles. source |
| Vaccinated vs unvaccinated | US 2025: 93% of cases unvaccinated or unknown status, 3% one MMR dose, 4% two doses. source England Jan-Mar 2025: 226 confirmed cases. 'Six cases (2.7%) had been previously vaccinated with one dose of the MMR vaccine and 5 (2.2%) with at least two doses.' source About 95% of children develop antibodies after one dose at 12 months, over 99% after two doses. source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average: 530,217 reported cases (estimated true 3-4 million/yr) vs 1,975 reported in 2025. source pre-vaccine England & Wales 1940-1967 (before vaccine, 1968): typically 160,000-760,000 notifications and 30-1,100 deaths a year; e.g. 1967: 460,407 notifications, 99 deaths. source |
| Products (see ingredients) | ProQuad (MMRV) Priorix-Tetra (MMRV) M-M-R II (MMR) Priorix (MMR, US licence 2022) |
Share-of-cases figures do not on their own give the risk for a vaccinated vs unvaccinated person (that needs the size of each group).
↑ all diseasesMumps
A virus that swells the salivary glands; can cause deafness, meningitis, swollen testicles.
| How common now (UK) | 2024 152 lab-confirmed cases in England in 2024. source |
|---|---|
| How common now (US) | 2025 336 reported cases in 2025. source |
| How often it kills | 'Permanent sequelae and death are very rare in both vaccinated and unvaccinated patients.' (no numeric CFR given) source |
| Treatment if caught | No specific treatment; NHS: 'Mumps usually gets better without treatment within 2 weeks.' source |
| Vaccinated vs unvaccinated | Vaccine effectiveness: 78% (one dose), 88% (two doses). source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 162,344 cases vs 336 in 2025 (>99% decrease). source |
| Products (see ingredients) | ProQuad (MMRV) Priorix-Tetra (MMRV) M-M-R II (MMR) Priorix (MMR, US licence 2022) |
Rubella (German measles)
Usually mild in children, but infection in early pregnancy can cause miscarriage or serious birth defects (congenital rubella syndrome).
| How common now (UK) | 2024 No lab-confirmed rubella cases in England in 2024. source |
|---|---|
| How common now (US) | 2025 0 rubella cases and 1 congenital rubella syndrome case reported in 2025. source |
| How often it kills | Main harm is congenital rubella syndrome (deafness, eye defects, heart disease); risk highest in first 12 weeks of pregnancy. No CFR given. source |
| Treatment if caught | No specific antiviral treatment for rubella (CDC). source |
| Vaccinated vs unvaccinated | At least 95% develop immunity after one dose; >90% protected against clinical rubella for at least 15 years. source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 47,745 rubella cases and 152 CRS cases vs 0 and 1 in 2025. source |
| Products (see ingredients) | ProQuad (MMRV) Priorix-Tetra (MMRV) M-M-R II (MMR) Priorix (MMR, US licence 2022) |
Chickenpox (varicella)
Itchy blister rash, usually mild in children; can cause skin infections, pneumonia, brain swelling. Now routine in UK (MMRV from Jan 2026) and US.
| How common now (UK) | 2004-2017 Not a notifiable disease in England, so no case count. England averaged 4,694 varicella hospital admissions/year (2004-2017); an earlier analysis estimated 18.5 deaths/year (2004-2013). source source 2 |
|---|---|
| How common now (US) | 2022 34,238 cases (2022, provisional). source |
| How often it kills | About 1 per 100,000 cases in children 1-14; 6 per 100,000 aged 15-19; 21 per 100,000 in adults (pre-vaccine US data). Newborns whose mother has chickenpox around delivery: up to 30% if antivirals not given. source |
| Treatment if caught | Usually supportive; antivirals (e.g. acyclovir) for severe disease/high-risk people. source |
| Vaccinated vs unvaccinated | 1 dose: 82% effective vs any chickenpox, 98% vs severe; 2 doses: 92% vs any chickenpox. source |
| Before vaccines vs now | pre-vaccine vs 2022 US pre-vaccine estimate 4,085,120 cases/yr vs 34,238 (2022): 99% decrease; ~10,500 hospitalisations/yr pre-vaccine. source |
| Products (see ingredients) | ProQuad (MMRV) Priorix-Tetra (MMRV) Varivax (chickenpox) |
Whooping cough (pertussis)
Bacterial infection with long coughing fits; most dangerous for babies under 6 months.
| How common now (UK) | 2024 14,879 lab-confirmed cases in England in 2024 (highest since 1994); 11 infant deaths. source |
|---|---|
| How common now (US) | 2024 35,435 cases in 2024 (provisional) with 10 deaths (6 infants); 28,132 reported in 2025. source source 2 |
| How often it kills | US 2000-2017: 307 deaths; pneumonia in 13.2% of all cases and 18.6% of infants <6 months. No single CFR given. source US 2024: infants <6 months had the highest hospitalisation rate (33.4%). source |
| Treatment if caught | Mainly supportive; antibiotics (azithromycin, clarithromycin, erythromycin) help most if started early and reduce spread. source |
| Vaccinated vs unvaccinated | Vaccination in pregnancy (England): 91.5% effective vs infant death, 88.2% vs hospitalisation, 84.6% vs confirmed disease in infants <3 months. source England: 26 of 32 infant deaths since 2013 were in babies whose mothers were not vaccinated in pregnancy. source Infant DTaP efficacy 80-85% (trials). source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 200,752 cases vs 28,132 in 2025 (86% decrease). source |
| Products (see ingredients) | Infanrix hexa Vaxelis REPEVAX (dTaP/IPV pre-school booster) Daptacel (DTaP) Infanrix (DTaP) Pediarix (DTaP-HepB-IPV) Pentacel (DTaP-IPV/Hib) Kinrix (DTaP-IPV) Quadracel (DTaP-IPV) Boostrix (Tdap) Adacel (Tdap) |
Diphtheria
Bacterial throat infection whose toxin can block airways and damage heart and nerves.
| How common now (UK) | 2024 England 2024: 2 toxigenic C. diphtheriae cases (+10 C. ulcerans), no deaths. source |
|---|---|
| How common now (US) | 2025 0 cases in 2025. source |
| How often it kills | Overall case fatality 5-10%. source |
| Treatment if caught | Diphtheria antitoxin plus antibiotics. source |
| Vaccinated vs unvaccinated | Toxoid vaccine efficacy estimated at 97%. source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 21,053 cases vs 0 in 2025. source |
| Products (see ingredients) | Infanrix hexa Vaxelis REPEVAX (dTaP/IPV pre-school booster) REVAXIS (Td/IPV teenage booster) Daptacel (DTaP) Infanrix (DTaP) Pediarix (DTaP-HepB-IPV) Pentacel (DTaP-IPV/Hib) Kinrix (DTaP-IPV) Quadracel (DTaP-IPV) Boostrix (Tdap) Adacel (Tdap) |
Tetanus (lockjaw)
Not caught from people - bacteria in soil enter wounds; toxin causes painful muscle spasms.
| How common now (UK) | 2024 England 2024: 6 cases, 2 deaths. source |
|---|---|
| How common now (US) | 2025 37 cases in 2025. source |
| How often it kills | About 11% of recent US cases fatal; highest in people 60+ and the unvaccinated. source |
| Treatment if caught | Wound cleaning; tetanus immune globulin (TIG); supportive care and airway management for spasms. source |
| Vaccinated vs unvaccinated | Never tested in a trial; inferred from antibody levels to be almost 100% effective after a full series. source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 580 cases vs 37 in 2025. source |
| Products (see ingredients) | Infanrix hexa Vaxelis REPEVAX (dTaP/IPV pre-school booster) REVAXIS (Td/IPV teenage booster) Daptacel (DTaP) Infanrix (DTaP) Pediarix (DTaP-HepB-IPV) Pentacel (DTaP-IPV/Hib) Kinrix (DTaP-IPV) Quadracel (DTaP-IPV) Boostrix (Tdap) Adacel (Tdap) |
Polio
Virus spread through faeces; most infections are mild but some cause permanent paralysis.
| How common now (UK) | 2022 No paralytic cases. In 2022, vaccine-derived poliovirus type 2 was found in London sewage. source |
|---|---|
| How common now (US) | 2025 0 paralytic cases reported in 2025. source |
| How often it kills | Paralytic polio: 2-5% of children and 15-30% of adolescents/adults die. source |
| Treatment if caught | WHO: 'There is no cure for polio, it can only be prevented.' source |
| Vaccinated vs unvaccinated | IPV: 90%+ immune after 2 doses, at least 99% after 3. source |
| Before vaccines vs now | pre-vaccine vs 2025 US 20th-century annual average 16,316 paralytic cases (21,000+ in 1952) vs 0 in 2025. source |
| Products (see ingredients) | Infanrix hexa Vaxelis REPEVAX (dTaP/IPV pre-school booster) REVAXIS (Td/IPV teenage booster) Pediarix (DTaP-HepB-IPV) Pentacel (DTaP-IPV/Hib) Kinrix (DTaP-IPV) Quadracel (DTaP-IPV) IPOL (polio, IPV) |
Hib (Haemophilus influenzae type b)
Bacteria causing meningitis, blood infection and throat swelling, mainly in under-5s.
| How common now (UK) | 2024 15 lab-confirmed invasive Hib cases in England in 2024 (none in infants); 2 adult deaths. source |
|---|---|
| How common now (US) | 2025 21 Hib cases in children <5 in 2025 (+ ~7 estimated among unknown serotype). source |
| How often it kills | Hib meningitis: 3-6% die even with treatment (pre-vaccine era data). source |
| Treatment if caught | Hospital treatment with antibiotics, usually 10 days. source |
| Vaccinated vs unvaccinated | Clinical efficacy 95-100%; invasive Hib down >99% since pre-vaccine era. source |
| Before vaccines vs now | pre-vaccine vs 2025 US: ~1 in 200 children under 5 developed invasive Hib; ~20,000 cases/yr vs 21 in 2025. source source 2 |
| Products (see ingredients) | Infanrix hexa Vaxelis Pentacel (DTaP-IPV/Hib) ActHIB (Hib) Hiberix (Hib) PedvaxHIB (Hib) |
Hepatitis B
Blood-borne liver virus; babies infected at birth usually become lifelong carriers, risking cirrhosis and liver cancer.
| How common now (UK) | 2022 239 acute hepatitis B diagnoses reported in England in 2022 (average 342 a year, 2015-2022); ~268,767 people living with chronic hep B (0.58%, 2021 estimate); 0.4% of pregnant women screened positive (2023-24). source source 2 |
|---|---|
| How common now (US) | 2023 2,214 reported acute cases in 2023 (estimated 14,400 infections). source |
| How often it kills | Up to 90% of infants infected at birth become chronically infected; 30-50% if infected age 1-5; ~5% in adults. source |
| Treatment if caught | Acute: supportive. Chronic: monitoring and antiviral medicines. Babies of infected mothers get vaccine plus hepatitis B immune globulin at birth. source |
| Vaccinated vs unvaccinated | Over 90% of infants, children, teenagers and healthy adults under 40 make protective antibodies after the full series; 80-100% effective at preventing infection or clinical hepatitis. source |
| Before vaccines vs now | pre-vaccine vs 2021 US pre-vaccine estimate 66,232 acute cases/yr vs 13,300 (2021 estimate): 80% decrease. source |
| Products (see ingredients) | Infanrix hexa Vaxelis Engerix-B (hep B) Recombivax HB (hep B) Pediarix (DTaP-HepB-IPV) |
UK gives the birth dose only to babies of mothers with hep B; US birth-dose policy was changed in Dec 2025 then restored by court order in March 2026.
↑ all diseasesHepatitis A
Liver virus spread through contaminated food/water or close contact; usually mild in young children. Routine in US only.
| How common now (UK) | 2024 Not on UK routine schedule. 889 new lab-confirmed acute hepatitis A cases in England and Wales in 2024 (496 in 2023). source |
|---|---|
| How common now (US) | 2023 1,648 reported cases in 2023 (estimated 3,300 infections); 85 hepatitis A-related deaths. source |
| How often it kills | 0.3-0.6% overall; up to 1.8% in adults 50+. source |
| Treatment if caught | No specific treatment; supportive. source |
| Vaccinated vs unvaccinated | Havrix: 94% efficacy (40,000 children, Thailand); Vaqta: 100% (1,000 children, New York). source |
| Before vaccines vs now | pre-vaccine vs 2021 US pre-vaccine estimate 117,333 cases/yr vs 11,500 (2021 estimate). source |
| Products (see ingredients) | Havrix (hep A) Vaqta (hep A) |
Meningococcal group B (MenB)
Bacteria causing meningitis and blood poisoning (sepsis); can kill within hours.
| How common now (UK) | 2023-24 England 2023-24: 341 invasive meningococcal cases, 301 (88%) group B; 8 deaths (provisional CFR 2.3%). source |
|---|---|
| How common now (US) | 2023 437 meningococcal cases (all groups) in 2023, 0.13 per 100,000; CFR 10.5%. MenB is not routine for all US children (shared decision, age 16-23). source |
| How often it kills | Overall CFR 10-15% even with antibiotics; up to 20% of survivors have lasting damage (hearing loss, brain damage, limb loss). source |
| Treatment if caught | Emergency antibiotics (e.g. ceftriaxone, penicillin) in hospital. source |
| Vaccinated vs unvaccinated | Bexsero in England: early estimate 82.9% effective after 2 doses (study reports range up to 94.2%). source |
| Products (see ingredients) | Bexsero (MenB) Trumenba (MenB) Penbraya (MenABCWY) |
Meningococcal groups A, C, W, Y
Same illness as above, other strains; teenage MenACWY dose in both countries.
| How common now (UK) | 2023-24 Included in the 341 England cases above (non-B groups ~12%). source |
|---|---|
| How common now (US) | 2023 2023: group Y caused 230 of 437 cases; CFR for group Y 9.6%. source |
| How often it kills | Overall CFR 10-15%. source |
| Treatment if caught | Emergency antibiotics. source |
| Vaccinated vs unvaccinated | US adolescents (MenACWY-D): 69% overall effectiveness, waning from 79% (<1 year) to 61% (3-8 years). source |
| Products (see ingredients) | MenQuadfi (MenACWY) Menveo (MenACWY) Penbraya (MenABCWY) |
Pneumococcal disease
Bacteria causing pneumonia, ear infections, blood infection and meningitis.
| How common now (UK) | 2022-23 England 2022-23: 4,598 lab-confirmed invasive cases; 378 in children under 15. source source 2 |
|---|---|
| How common now (US) | 2021 Invasive disease 2021 estimate: 17,400 all ages; ~900 in children under 5. source |
| How often it kills | Bacteremia ~12%; pneumococcal meningitis ~14% in adults; bacteremic pneumonia ~10%. source |
| Treatment if caught | Antibiotics. CDC: some strains resist one or more antibiotics, which 'can lead to treatment failures'. source |
| Vaccinated vs unvaccinated | PCV13 in adults 65+ (trial): 75% efficacy vs vaccine-type invasive disease. source US under-5 invasive disease: 16,069/yr pre-vaccine vs ~900 now (94% fall). source |
| Before vaccines vs now | pre-vaccine vs 2021 US pre-vaccine estimate 63,067 invasive cases/yr (all ages) vs 17,400 (2021); under 5: 16,069 vs 900; ~200 child deaths/yr pre-vaccine. source source 2 |
| Products (see ingredients) | Prevenar 13 / Prevnar 13 (PCV13) Vaxneuvance (PCV15) Prevnar 20 / Prevenar 20 (PCV20) |
Rotavirus
Stomach bug causing severe diarrhoea and vomiting in babies; dehydration is the danger.
| How common now (UK) | 2023-24 3,199 positive lab reports in England, 2023-24 season (to 30 June 2024). source |
|---|---|
| How common now (US) | 2022 ~18,400 hospitalisations in children <3 (2022 estimate). source |
| How often it kills | US pre-vaccine: 20-60 deaths/yr in children <5 (55,000-70,000 hospitalisations); deaths rare in high-income countries. source |
| Treatment if caught | Supportive: fluids/rehydration; keep feeding. source |
| Vaccinated vs unvaccinated | US: 84% (RotaTeq) and 83% (Rotarix) effective vs ER visit or hospitalisation. source England: 77-88% fewer infant infections in 5 years after vaccine introduction (2013). source |
| Before vaccines vs now | pre vs post vaccine England & Wales lab reports: 14,950 in 2013 (pre-vaccine) vs 2,705 in 2016. source pre-vaccine vs 2022 US: 62,500 hospitalisations/yr (<3 years) pre-vaccine vs 18,400 (2022). source |
| Products (see ingredients) | Rotarix (rotavirus, oral) RotaTeq (rotavirus, oral) |
HPV (human papillomavirus)
Very common sexually transmitted virus; some types cause cervical and other cancers and genital warts.
| How common now (UK) | 2019-2024 3,299 new cervical cancer cases a year (2019, 2021-22) and 880 deaths a year (2022-24), UK. source |
|---|---|
| How common now (US) | recent annual estimate About 49,908 HPV-associated cancers a year, incl. 12,287 cervical (≈11,100 attributable to HPV). source |
| How often it kills | Not applicable as a single figure - infection usually clears; harm is cancer years later. source |
| Treatment if caught | No treatment for the infection itself; warts, pre-cancers and cancers are treated. Screening prevents most cervical cancers. source |
| Vaccinated vs unvaccinated | England: 87% lower cervical cancer in women offered vaccine at 12-13 vs unvaccinated cohorts (97% lower CIN3). source source 2 US: within 10 years, vaccine-type HPV prevalence down 86% in females 14-19. source |
| Before vaccines vs now | pre-vaccine US pre-vaccine (2003-06): an estimated 79 million infected; 14 million new infections/yr. source |
| Products (see ingredients) | Gardasil 9 (HPV) |
Flu (influenza)
Seasonal respiratory virus; most serious in the very old, very young and people with health conditions.
| How common now (UK) | 2024-25 Estimated 53 flu-related deaths in children under 18 in England, 2024-25 season (35 in 2023-24). source |
|---|---|
| How common now (US) | 2024-25 280 flu-associated child deaths in 2024-25 season. Annual deaths, all ages: 12,447-61,099 (2010-2019 seasons). source source 2 |
| How often it kills | Varies widely by season and age; most deaths in people 65+. source |
| Treatment if caught | Antiviral medicines (e.g. oseltamivir) for some patients; supportive care. source |
| Vaccinated vs unvaccinated | US 2024-25: of 208 child deaths with known status (age 6 months+), 89% were not fully vaccinated. source Vaccine effectiveness 19-60% (2010-11 to 2018-19 seasons), varying by strain match. source |
| Products (see ingredients) | Fluenz Tetra (2020) / Fluenz (current, nasal flu) Fluzone Trivalent 2026-27 (flu injection) Fluarix 2026-27 (flu injection) FluLaval 2026-27 (flu injection) Flucelvax 2026-27 (flu injection, cell-grown) Flublok 2026-27 (flu injection, recombinant) FluMist 2026-27 (nasal spray, live) Afluria (flu injection) |
COVID-19
Respiratory virus. UK offers the vaccine only to at-risk groups; US lists it as 'shared clinical decision-making' for children.
| How common now (UK) | 2020-21 Not on UK routine childhood schedule. England, Mar 2020-Feb 2021: 25 deaths of under-18s were due to COVID-19 (of 61 who died with a positive test), out of 12.0 million children. source |
|---|---|
| How common now (US) | 2024-25 187 COVID deaths in under-18s (July 2024-June 2025). Highest child hospitalisation rate in infants <6 months: 285.6 per 100,000. source |
| How often it kills | England under-18s, Mar 2020-Feb 2021 (wild-type and Alpha variants): infection fatality rate about 5 per 100,000 infected (0.005%); 99.995% of those with a positive test survived. source US: GAP - no case-fatality rate for children found in a primary source. |
| Treatment if caught | Antivirals for people at high risk of severe illness: Paxlovid (age 12+), remdesivir (adults and children), molnupiravir (adults), started within 5-7 days of symptoms. source |
| Vaccinated vs unvaccinated | US infants <6 months hospitalised Oct 2022-Apr 2024: 87.5% had mothers not vaccinated in pregnancy; all 9 in-hospital deaths were in that group (share of cases, not a risk ratio). source |
| Products (see ingredients) | Comirnaty (Pfizer-BioNTech COVID-19, mRNA) Spikevax (Moderna COVID-19, mRNA) |
RSV (respiratory syncytial virus)
Common winter virus; can cause bronchiolitis and breathing trouble in babies. Protected by a vaccine in pregnancy (UK and US) or an antibody shot for babies (US).
| How common now (UK) | pre-2024 / 2025-26 Before the vaccine: about 30,000 hospitalisations of under-5s a year in the UK and 20-30 infant deaths. 2025-26: 50% fewer infants under 6 months in intensive care with RSV in England than the season before. source source 2 |
|---|---|
| How common now (US) | annual estimate 58,000-80,000 RSV hospitalisations a year in children under 5. source source 2 |
| How often it kills | UK: 20-30 infant deaths a year (pre-vaccine); no case-fatality rate published. US: GAP - no annual RSV death count or CFR for children found in a primary source. source |
| Treatment if caught | Supportive care; CDC: most hospitalised patients 'improve with supportive care and are discharged in a few days'. source |
| Vaccinated vs unvaccinated | Nirsevimab (antibody): 90% effective vs RSV hospitalisation in infants' first season (early estimate). source Maternal Abrysvo (UK, 2024-25): 58% effective vs infant RSV hospitalisation, 72% if given >14 days before birth. source source 2 UK 2025-26: 61% effective vs hospital admission in infants up to 6 months, 76% up to 3 months. source US infants 0-7 months: RSV hospitalisation rate 43% lower in 2024-25 than 2018-20. source |
| Products (see ingredients) | Abrysvo (RSV, given in pregnancy) Beyfortus (nirsevimab) - monoclonal antibody, not a vaccine Enflonsia (clesrovimab) - monoclonal antibody, not a vaccine |
Vitamin K deficiency bleeding (not a vaccine)
Babies are born low in vitamin K; rarely this causes bleeding, sometimes in the brain. The birth injection is vitamin K, not a vaccine.
| How common now (UK) | About 1 in 8,500 babies without vitamin K (secondary source quoting NHS). source |
|---|---|
| How common now (US) | Late VKDB: 4.4 to 7.2 per 100,000 infants without vitamin K. source |
| How often it kills | No UK or US death rate found. Egypt, 5-year study of 47 infants with late VKDB: 11 died (23%). Small study, not UK/US. source |
| Vaccinated vs unvaccinated | Infants without the vitamin K shot are 81 times more likely to develop late VKDB. source |
| Ingredients (official leaflet) | UK, Konakion MM Paediatric 2 mg/0.2 ml: phytomenadione (vitamin K1) 2 mg; glycocholic acid, lecithin, sodium hydroxide, hydrochloric acid, water for injections. source source US, Hospira Vitamin K1 injection: phytonadione 2 mg or 10 mg per mL; polyoxyethylated fatty acid derivative 70 mg, dextrose (hydrous) 37.5 mg, water for injection, benzyl alcohol 9 mg (preservative); may contain hydrochloric acid. source Other US makers: labels differ. Some list polyoxyl 35 castor oil, dextrose, benzyl alcohol, hydrochloric acid, water. Others list polysorbate 80, propylene glycol, sodium acetate, acetic acid, water (one adds cysteine hydrochloride). One lists polyoxyl 35 castor oil, dextrose, citric acid, sodium phosphate, hydrochloric acid, water with no benzyl alcohol. source |
| Products (see ingredients) | Konakion MM Paediatric (vitamin K1, phytomenadione) - NOT a vaccine Vitamin K1 injection (phytonadione, Hospira) - NOT a vaccine |
Newborn vitamin D (a supplement, not a vaccine)
Vitamin D drops (usually cholecalciferol, vitamin D3) are advised for breastfed babies from birth, to prevent rickets. Shown here next to vitamin K, the other newborn supplement in this guide.
What is given, and how
- NHS advises that breastfed babies "should be given a daily vitamin D supplement from birth, whether or not you're taking a supplement containing vitamin D yourself". NHS says the drops can be bought "at pharmacies and supermarkets". source source 2
- The UK Healthy Start leaflet says its drops "should be given by mouth (orally)", 5 drops once daily. source
- NIH ODS reports that supplements contain vitamin D2 (ergocalciferol) or D3 (cholecalciferol); D3 "is typically produced with irradiation of 7-dehydrocholesterol from lanolin obtained from the wool of sheep", and a lichen-sourced D3 also exists. source
- The Australasian Neonatal Medicines Formulary lists two routes for newborn colecalciferol, oral and intramuscular. Its prevention dose is 400 units a day by mouth. Intramuscular use is listed for treating rickets: "If oral administration is difficult, consider intramuscular vitamin D3 100,000 units (colecalciferol 2.5 mg) every 3 months (3 doses)." The injectable product it names holds 600,000 units per mL. source
- The 2016 global consensus on rickets describes "stoss therapy" as "the administration of a large dose given as a single dose or in divided doses over several days". It recommends daily treatment first but says "in some situations, stoss therapy may be more practical". On route, it says: "We recommend oral treatment, which more rapidly restores 25OHD levels than IM treatment." These are treatment doses for rickets, not routine newborn doses. source
- Thailand: a 2021 Thai trial reports that "routine vitamin D supplementation for exclusively breastfed infants has not been widely practiced" in Thailand and that "the local healthcare authorities have not established a national consensus". It also says no infant vitamin D-only product was on sale in Thailand when the study was done, so it used a multivitamin drop. source
- A 2024 Bangkok study states: "in Thailand, no advice for routine vitamin D supplementation is available." source
- GAP: this guide found no published source saying that Thai hospitals routinely give vitamin D as an injection on the day of birth, and no national Thai policy saying so. Practice may vary by hospital. The product name and dose on a baby's hospital discharge record would show what was given.
Recommended dose and why (UK and US)
- UK (NHS / Department of Health and Social Care): babies from birth to 1 year who are breastfed "should be given a daily supplement containing 8.5 to 10 micrograms of vitamin D". Babies having more than 500ml of infant formula a day should not be given one, because formula is already fortified. source
- NICE CKS gives the same UK dose in units: 8.5-10 micrograms is 340-400 international units (IU) a day. (1 microgram = 40 IU.) source source 2
- US (AAP): "Vitamin D supplements of 400 IU (10 mcg) per day are recommended for babies up until age one year." source
- CDC: the AAP and the Dietary Guidelines for Americans "recommend that breastfed and partially breastfed infants receive 400 International Units (IU) of vitamin D daily beginning in the first few days of life." source
- Why: the AAP's clinical report is titled "Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents". CDC states that vitamin D "helps prevent rickets, a condition that causes weak or deformed bones." source source 2
- NHS describes rickets as a condition caused by a lack of vitamin D or calcium; it says the main symptom is bowed legs. source
- The 2016 global consensus states: "400 IU/d (10 μg) is adequate to prevent rickets and is recommended for all infants from birth to 12 months of age, independent of their mode of feeding." source
- How common rickets is: NIH ODS reports 24.1 cases per 100,000 children under 3 in one Minnesota county (2000s), mainly in breastfed Black children, and 2.9 per 100,000 children under 7 in Canada (2002-2004), where "almost all patients with rickets had been breastfed". source
Ingredients in the drops (from manufacturers' leaflets and labels)
- Enfamil D-Vi-Sol (US): 10 mcg (400 IU) vitamin D per 1 mL. Other ingredients: "Glycerin, water, polysorbate 80 (emulsifier), citric acid (antioxidant for vitamin D), natural flavor, sodium citrate." source
- Baby Ddrops: 400 IU per drop, "made with only two naturally sourced ingredients, pure vitamin D3 and organic fractionated coconut oil". The maker states it is free from preservatives. source
- Healthy Start children's vitamin drops (UK government scheme): 5 drops contain vitamin D 7.5 micrograms (300 IU), vitamin A 233 micrograms and vitamin C 20 mg. Other ingredients: "water, glycerol, polysorbate 80, banana flavour, alpha-tocopherol, Medium Chain Triglycerides." (This leaflet was last approved in 05/2018.) source
- The ANMF notes that some vitamin D preparations contain sodium benzoate, and advises: "Avoid exposure to sodium benzoate of >99 mg/kg/day in neonates." source
- The Thai trial used Munti-Vim multivitamin drops (B.L. Hua, Bangkok), with 400 IU vitamin D3 per mL plus vitamins A, B1, B2, B6, B12, C, nicotinamide and dexpanthenol. source
Cholecalciferol as a rat poison (EPA)
- US EPA: "Cholecalciferol is vitamin D3, which in small dosages is needed for good health in most mammals, but in massive doses is toxic, especially to rodents." source
- EPA's label database lists Cholecalciferol Blox (EPA Reg. No. 12455-162), a registered rat and mouse bait, with cholecalciferol at 0.075% as the active ingredient. source
- An EPA risk assessment memo states that cholecalciferol works as a rodenticide by mobilising "calcium from bones into the blood plasma causing hypercalcemia". The same memo notes that it is a nutrient permitted as a food additive and is generally recognised as safe as a dietary supplement "within specific limitations". source
- NPIC reports that cholecalciferol was first registered as a rodenticide in the US in 1984. "The body's ability to maintain proper calcium levels must be overwhelmed before cholecalciferol becomes toxic. Rodents must eat several doses." It adds that "poisonings of people are very rare." source
- This guide's own arithmetic 0.075% means 0.75 mg of cholecalciferol per gram of bait, which is 750 micrograms, or 30,000 IU. One infant daily dose is 10 micrograms (400 IU). So 1 gram of bait holds about 75 infant daily doses, and one infant daily dose equals the vitamin D in about 13 mg of bait. source source 2
- This guide's own arithmetic Concentration compared: D-Vi-Sol has 10 micrograms per mL. The bait (750 micrograms per gram) is about 75 times as concentrated, taking 1 mL as about 1 gram. The newborn injection product named by the ANMF (600,000 units/mL = 15 mg/mL) is about 20 times as concentrated as the bait. The effect depends on the total amount swallowed or injected, not on concentration alone. source source 2
Too much vitamin D in infants: evidence, warnings and recalls
- Upper limits: NIH ODS gives the US upper intake level as 1,000 IU (25 mcg) a day for 0-6 months and 1,500 IU (38 mcg) for 7-12 months. NHS says infants under 12 months "should not have more than 25 micrograms (1,000 IU) a day". source source 2
- NIH ODS: too much vitamin D causes high blood calcium, which can lead to nausea, vomiting, muscle weakness, dehydration and kidney stones, and in extreme cases kidney failure, heart rhythm problems and death. It says toxicity has been caused by supplements with excess vitamin D "because of manufacturing errors", supplements taken in excessive amounts, and wrong prescriptions. It also says too much sun does not cause vitamin D toxicity. source
- The ANMF reports that 1,600 units/day of vitamin D3 "produced vitamin D toxicity (hypercalcaemia and 25OH vitamin D >250 nmol/L) in 94% of healthy, term, breastfed infants" in the study it cites, and that a single 600,000-unit dose in infants "produced prolonged vitamin D excess and transient hypercalcaemia, whereas doses of 100,000 to 200,000 units every 3 months did not." source
- In a stoss-therapy study cited by the 2016 consensus, 56 Turkish children aged 3-36 months were given single oral doses of 150,000, 300,000 or 600,000 IU, and eight developed high blood calcium (two in the 300,000 group, six in the 600,000 group). source
- 2010 FDA, June 2010: FDA had seen "an increase in the number of liquid vitamin D dietary supplements being marketed that could lead to infants receiving an unsafe amount of vitamin D", because droppers could hold more than an infant should get. It recommended that droppers for infant products "hold no more than 400 units". source
- 2024 Recall, February 2024 (FDA notice): Nordic Naturals recalled one lot (234909) of Baby's Vitamin D3 Liquid, about 3,800 units, after "a manufacturing error that resulted in an elevated level of Vitamin D3 dosage". The company reported no adverse events at that time. source
- Case report (US): a 3-month-old was given 1 mL a day of a new product that held 400 IU per drop rather than per mL. That came to 12,000 IU a day, a 30-fold overdose, for 20 days. The authors say the infant was "clinically stable with no symptoms" when the error was found. source
- 2023 France (ANSES, 2023): ANSES received three reports in 2022 of severe high blood calcium in infants who were given internet-bought food supplements containing 5,000-10,000 IU per drop, in one case 40,000 IU a day. The reports included kidney calcium deposits (nephrocalcinosis) and, in one infant, an ECG abnormality. ANSES advises against replacing medicinal vitamin D with a food supplement. source
- 2022 Case report (France, 2022): a 3-month-old developed severe high blood calcium after the parents, on a midwife's advice, swapped the prescribed medicinal vitamin D for a "natural" dietary supplement of a different concentration. source
Natural sources, D2 versus D3, and breast milk
- Sunlight: NIH ODS explains that UVB light (about 290-320 nm) on bare skin turns 7-dehydrocholesterol into previtamin D3, which becomes vitamin D3. UVB does not pass through glass. source
- NIH ODS reports that the AAP advises keeping infants under 6 months out of direct sunlight. NHS says: "Young children should still have vitamin drops, even if they get out in the sun." source source 2
- A Bangkok study of 109 exclusively breastfed 4-month-olds found 35.78% vitamin D deficient and 33.03% insufficient. Their "sun index showed no correlation with the 25-OH vitamin D level". source
- Foods (NIH ODS table, per serving): farmed rainbow trout, 3 oz cooked: 645 IU; sockeye salmon, 3 oz cooked: 570 IU; one large egg: 44 IU ("Vitamin D is in the yolk"); white mushrooms exposed to UV light, ½ cup: 366 IU (vitamin D2); ordinary portabella mushrooms, ½ cup: 4 IU. source
- D2 versus D3: Tripkovic 2012 (meta-analysis) concluded that "vitamin D3 is more efficacious at raising serum 25(OH)D concentrations than is vitamin D2". The difference was significant with a bolus dose, "but the effect was lost with daily supplementation". The authors said effects "across age, sex, and ethnicity" could not be checked. source
- The 2016 global consensus states: "For daily treatment, both D2 and D3 are equally effective" and "When single large doses are used, D3 appears to be preferable compared to D2 because the former has a longer half-life." NIH ODS says the two forms "seem to have equivalent ability to cure rickets". source source 2
- Breast milk: NIH ODS states that "consumption of human milk alone does not ordinarily enable infants to meet vitamin D requirements, because it provides less than 0.6 to 2.0 mcg/L (25 to 78 IU/L)", and that the level depends on the mother's vitamin D status. CDC: "Breast milk alone does not provide infants with enough vitamin D." source source 2
- This guide's own arithmetic At the top of that range (78 IU per litre), a baby would need to drink more than 5 litres of breast milk a day to get 400 IU. source
- Mother's supplements: NIH ODS reports that breast milk from mothers taking at least 2,000 IU of D3 a day has higher levels, and CDC says families can discuss maternal high-dose supplements with a provider. The 2016 consensus recommends: "Lactating women should not take high amounts of vitamin D as a means of supplementing their infant." source source 2